Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 6/20 | 0.39 |
| ▸ | CNR2 | P34972 | 6/20 | 0.39 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.36 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.36 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | P4HB | P07237 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30983884 | 0.98 | PDK2 (0.39) | PDK2CNR1CNR2NPFFR1NPFFR2 | |
| SCHEMBL30983397 | 0.89 | PIK3CD (0.34) | CNR1CNR2PIK3CD | |
| SCHEMBL30983529 | 0.89 | PDK2 (0.38) | PDK2CNR1CNR2PIK3CD | |
| SCHEMBL30983583 | 0.87 | PIK3CD (0.34) | CNR1CNR2PIK3CD | |
| SCHEMBL31321937 | 0.86 | PLA2G2A (0.40) | PDK2PIK3CD | |
| SCHEMBL30983802 | 0.85 | CNR1 (0.43) | CNR1CNR2RETPIK3CDBRD4 | |
| SCHEMBL30983954 | 0.84 | PLA2G2A (0.39) | CNR1CNR2PIK3CD | |
| SCHEMBL30983539 | 0.84 | PIK3CD (0.37) | CNR1CNR2PIK3CD | |
| SCHEMBL30983867 | 0.84 | PIK3CD (0.37) | CNR1CNR2PIK3CD | |
| SCHEMBL30983924 | 0.83 | PLA2G2A (0.38) | CNR1CNR2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| EP-4630410-A1 | POLQ INHIBITORS | Astrazeneca AB (SE) | 2025-10-15 | — | — | EP | disclosed |
| US-12414954-B2 | POLQ inhibitors | ASTRAZENECA AB (SE) | 2025-09-16 | — | — | US | disclosed |
| US-20250195530-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2025-06-19 | — | — | US | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024121753-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2024-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12414954-B2 | POLQ inhibitors | POLQ, POLG, POLB | PDK2 1482/4885CNR1 4278/4885CNR2 4639/4885 |
| US-20250195530-A1 | POLQ INHIBITORS | POLQ, POLG, POLB | PDK2 1482/4885CNR1 4278/4885CNR2 4639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.